Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
Dermata expects its second commercial skincare product to launch in H1 2027, with trial data intended to support commercialization.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dermata Therapeutics (DRMA) enrolled the first participant in a clinical trial evaluating Tome Clearing Treatment, its planned second commercial skincare product. The company expects to launch the once-weekly acne treatment in H1 2027. It combines salicylic acid, an FDA-recognized over-the-counter acne active ingredient, with Dermata's Bioneedle powder.
The open-label study, in which treatment is known, is expected to enroll approximately 24 participants with facial acne. Participants will apply the treatment weekly for 12 weeks, with an optional additional 12 weeks. A dermatologist will assess acne lesion counts, overall acne treatment response and post-inflammatory hyperpigmentation, or dark marks after inflammation. Dermata intends to use the data to support marketing and commercialization. Its first product, Tome Foundational Treatment, is already commercially available.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Dermata expects to launch its second commercial product in H1 2027.
- Minor pointFirst participant enrolled in the Tome Clearing Treatment acne clinical trial.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Open-label study is expected to enroll approximately 24 participants, limiting the scope of the clinical evaluation.
Key Figures
- Planned enrollment
- Approximately 24 participants
- Open-label acne study
- Treatment schedule
- Once weekly for 12 weeks
- Tome Clearing Treatment study
- Optional treatment extension
- Additional 12 weeks
- Participants may elect to continue
- IGA scale
- 0 to 4 (five-point scale)
- Investigator Global Assessment
- IGA treatment response
- At least a 1-point improvement and an IGA score of 0 or 1
- Study response definition
- Expected product launch
- H1 2027
- Tome Clearing Treatment
- Annual U.S. acne prevalence
- Approximately 50 million Americans
- Population cited in the article
Key Terms
open-label medical
investigator global assessment medical
post-inflammatory hyperpigmentation medical
acne vulgaris medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / October 29, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company's once-weekly acne treatment, in participants with acne. The Company expects to launch this second commercial product in H1 2027.
The initiation of this clinical trial marks another milestone in Dermata's strategy by adding a second product to its Tome skincare portfolio, targeting significant opportunities in the consumer skincare market. Acne affects approximately 50 million Americans annually, representing a substantial market for accessible, effective, and convenient treatment options. Tome Clearing Treatment kits salicylic acid, an FDA-recognized over-the-counter ("OTC") acne active ingredient, with Dermata's Bioneedle™ powder in a differentiated once-weekly treatment regimen. The study is designed to evaluate improvements in acne lesions and post-inflammatory hyperpigmentation, with the goal of generating clinical evidence to support the product's planned commercialization.
"With our Tome Foundational Treatment for skin renewal now commercially available, we are focused on driving growth of our Tome skincare product portfolio and building a scalable business around our differentiated Bioneedle technology," said Gerry Proehl, Dermata's Chairman, President and Chief Executive Officer. "The initiation of this clinical trial represents an important step toward introducing our second Tome product, which we expect to launch in the first half of 2027. With most topical OTC acne treatments needing to be applied once or twice a day, we believe there is a meaningful commercial opportunity for an effective, convenient, once-weekly treatment that simplifies traditional acne care," Mr. Proehl continued. "Importantly, we believe our experience in dermatologic clinical development provides a competitive advantage as we build the Tome skincare brand. Our strategy is to combine differentiated products with clinical evidence that can help build consumer confidence, support our marketing efforts, and drive long-term growth," concluded Mr. Proehl.
Tome Clearing Treatment Clinical Trial Design
The clinical trial is expected to enroll approximately 24 participants with facial acne vulgaris in an open-label study. Participants will topically apply Tome Clearing Treatment once weekly for 12 weeks. A dermatologist will evaluate participants on endpoints including change from baseline in inflammatory and noninflammatory lesion counts, Investigator Global Assessment ("IGA") treatment response, and improvement in post-inflammatory hyperpigmentation. IGA is measured on a five-point scale from 0 to 4, with treatment response defined as at least a one-point improvement from baseline and an IGA score of 0 (clear) or 1 (almost clear). Participants may elect to continue treatment for an additional 12 weeks, which will help provide the Company with additional data regarding the safety and efficacy of Tome Clearing Treatment over an extended treatment period. The clinical data generated from this trial will help support marketing and commercialization of Tome Clearing Treatment.
Tome Clearing Treatment: A Once-Weekly Approach to Acne Care
Tome Clearing Treatment is a once-weekly acne routine powered by salicylic acid, an FDA-recognized OTC acne active ingredient, and Bioneedle™, Dermata's hero ingredient derived from
About Acne Vulgaris
Acne is one of the most common skin conditions in the United States, affecting approximately 50 million people. It can include noninflammatory lesions such as blackheads and whiteheads, inflammatory papules and pustules, and, in more severe cases, cysts and scarring. Acne can occur beyond adolescence and may affect the face, neck, chest, back, shoulders and upper arms. In addition to its physical effects, acne can have a negative impact on quality of life and self-esteem. Over
About Tome Skincare
Tome is Dermata's skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome, in its literal meaning, is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome consists of skincare products utilizing a wild harvested freshwater sponge that has evolved over centuries, for consumers compelled by history and science to find potent natural products for their skincare routine. Dermata believes its Tome skincare line can simplify existing skincare routines with essential ingredients designed to deliver results, without harmful extremes.
Start your skincare story at Tome.
About Dermata Therapeutics
Dermata Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer and professional skincare solutions. The Company leverages its experience in clinical dermatology and its Bioneedle technology to develop differentiated skincare products designed to address a variety of consumer skincare needs. Dermata's first commercial product, Tome Foundational Treatment, is now available at Tome, with its second planned product, Tome Clearing Treatment, expect to launch in H1 2027. Dermata is headquartered in San Diego, California. For more information, please visit Dermata.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to commercialize skincare products; the timing of any future announcements; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, market acceptance of its products, and expansion into broader consumer markets; the expected timing and success of any planned product launches; the potential market acceptance of any products; the proposed benefits any clinical data will provide any products; the Company's plan to incorporate study results into any marketing activities; whether the FDA will agree the Clearing Treatment complies with the applicable OTC monograph; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Dermata Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Dermata expect to launch Tome Clearing Treatment?
Dermata expects to launch Tome Clearing Treatment in H1 2027 as its second commercial product. The company has enrolled the first participant in a clinical trial intended to support the product's marketing and commercialization.
How does Dermata's Tome Clearing Treatment trial define overall acne treatment response?
The trial defines Investigator Global Assessment treatment response as at least a one-point improvement from baseline and a score of 0 (clear) or 1 (almost clear). This dermatologist-rated assessment uses a five-point scale from 0 to 4.